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β amyloidFE65 proteins constitute a family of adaptors which modulates the processing of amyloid precursor protein
and the consequent amyloid β production. Thus, they have been involved in the complex and partially un-
known cascade of reactions at the base of Alzheimer's disease etiology. However, FE65 and FE65-like proteins
may be linked to neurodegeneration through the regulation of cell cycle in post-mitotic neurons. In this work
we disclose novel molecular mechanisms by which APBB2 can modulate APP processing. We show that APBB2
mRNA splicing, driven by the over-expression of a novel non-coding RNA named 45A, allow the generation of alter-
native protein forms endowed with differential effects on Aβ production, cell cycle control, and DNA damage re-
sponse. 45A overexpression also favors cell transformation and tumorigenesis leading to a marked increase of
malignancy of neuroblastoma cells. Therefore, our results highlight a novel regulatory pathway of considerable in-
terest linking APP processing with cell cycle regulation and DNA-surveillance systems, that may represent amolec-
ular mechanism to induce neurodegeneration in post-mitotic neurons.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
FE65 and FE65-like {FE65L1, also called APBB2 [Amyloid beta
(Aβ) precursor protein-binding, family B, member 2, NP_004298.1]
and FE65L2 (BAA78674.1)} proteins constitute a family of adaptors
which modulates the processing of amyloid precursor protein
(APP) and the consequent synthesis of amyloid β. Thus, these protein
adaptors have been involved in the complex and partially unknown
cascade of reactions at the base of Alzheimer's disease (AD) etiology
[1,2]. In particular, the direct involvement of APBB2 in AD may be
related to its propensity to vicariate APBB1 (Fe65). In fact, like APBB1,
APBB2 might participate to AD development altering APP processing
through an increased production of amyloid β [2] or interacting with
Tip60 [K (lysine) acetyltransferase 5, NC_000011.9] acting in the intracel-
lular compartment [3–8]. In both cases we must consider the possible
competition among APBB1 and APBB2 and 3, as APP-interacting proteins.IST, Genova, Italy. Tel.: +39
rights reserved.Indeed, it was reported that APBB2 co-localizes with the AICD
(Amyloid Intracellular C-terminal Domain) [9] and that a transcription-
ally active APBB1-AICD-Tip60 complex can be formed [10] thus bringing
to light an Aβ-independent contribution of APBB proteins to AD.
However, speciﬁc modulation of transcription for APBB2 has not been
described yet, suggesting that its inﬂuence on global gene-expression
might need to be mediated by other proteins [11]. Notwithstanding,
recent experimental observations showing that the AICD overexpression
lead to AD-like phenotype in vivo, suggest that the contribute of AICD
(and of the modulators of its functional activity) to AD onset might be
as relevant as that of the secreted portion of APP, Aβ [12].
Besides the role in gene expression and APP processing, its involve-
ment in cell cycle regulation is a further aspect of APBB2 biological func-
tion that might be linked to neurodegeneration. Indeed, it has been
reported that the overexpression of APBB2 in PC12 cells inhibits
cell cycle progression, via its nuclear translocation and inhibition of
thymidilate synthase (TYMS, NC_000018.9) leading, ultimately, to
a cell cycle delay [13]. In this context, although the link between
TYMS downregulation and AD pathogenesis is not clear yet, it was
proposed that this phenomenon might lead to a weakening of the
DNA repair apparatus with consequences on chromosomal stability
[13]. Thus, the high rate of aneuploidy detected in AD brains constitutes
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neurodegeneration, that deserves further investigations.
In this work we searched for molecular links among the multiple
roles played by APBB2 in APP processing starting from a novel aspect
of APBB2 biology: the synthesis of alternative protein forms with pecu-
liar biochemical features through mRNA maturation [11]. Among the
already characterized isoforms, the alternative splicing variants “a”,
“b” and “c” are very similarly spliced except for the lack of exon 8
(63 bp/21 residues-long stretch) in variant “c”. Despite the potential
relevance in neurophysiopathology of APBB2 alternative splicing, the
key factor(s) affecting this process and its tissue- and stage-speciﬁcity
are largely unknown.
We recently demonstrated that the pol III transcriptome is much
larger than expected and that a fraction of these non-coding (nc) RNAs
might act as speciﬁc regulators of gene expression of protein-coding
target [14–17]. Functional studies of two of these RNAs showed that
they map to an intronic portions of Pol II genes in antisense conﬁgura-
tion and, when expressed, perturb pre-mRNA maturation driving to
the synthesis of alternative protein forms with peculiar biological fea-
tures [18,19]. Here we report on a novel pol III-transcribed ncRNA
(hereafter referred to as 45A) that maps in the intron 1 of APBB2 in an-
tisense (AS) conﬁguration. In consideration of its sub-chromosomal
localization and previous studies on other small nuclear (sn) RNA-like
transcripts of our collection, we postulated the possible inﬂuence of
45A expression on APBB2 pre-mRNA maturation thus linking its geno-
mic location to its biological role.
Herein, we demonstrate that 45A expression leads APBB2-speciﬁc
pre-mRNA alternative maturation driving to the synthesis of alterna-
tive protein forms. In turn, these alternative APBB2 molecules perturb
the processing of APP C-terminal fragments (CTFs) and, concomitant-
ly, exert deep effects on cell cycle regulation, altering the synthesis of
cell cycle control- and DNA repair-related proteins. The phenotype
driven by 45A overexpression also favors cell transformation and tu-
morigenesis leading to amarked increase ofmalignancy of neuroblasto-
ma cells both in vitro and in vivo. Therefore, our results highlight a novel
pol III-dependent regulatory pathway of considerable interest linking
APP processingwith cell cycle regulation andDNA-surveillance systems
as a mechanism of neurodegeneration, and providing a novel possible
connection among different hypotheses on AD pathology.
2. Materials and methods
2.1. Cell culture, transfection and luciferase assay
Different cells lines were used: HEK-293 (Human Embryonic
Kidney), HeLa (Human epithelial cervical cancer), LoVo (Human
Colon Carcinoma) and SH-SY5Y (Human Neuroblastoma) cells were
maintained on Dulbecco's modiﬁed Eagles medium (DMEM ECB7501L,
EuroClone, Milan, Italy), 10% FBS (LONZA DE14-801F), L-glutamine
(2 mM; EuroClone, Milan, Italy), and penicillin–streptomycin (100 U/
ml/100 μg/ml; EuroClone,Milan, Italy). SKNBE2 (HumanNeuroblastoma)
cells were maintained on RPMI 1640 medium (ECB9006L EuroClone,
Milan, Italy), 10% FBS (LONZA DE14-801F), L-glutamine (2 mM;
EuroClone, Milan, Italy), penicillin–streptomycin (100 U/ml/100 μg/ml;
Euro Clone, Milan, Italy) (standard medium). HEK-293, SH-SY5Y and
HeLa cells were transfected using polyethylenimine (PEI; Sigma P3143),
SKNBE2 cells by a Microporator MP-100 (Digital Bio; NanoEnTek, Seoul,
Korea; Labtech France) with pEGFP-N1 as control (hereafter referred
to as HEK-M) and pEGFP-N1-45A (hereafter referred to as HEK-45A).
G418 (Geneticin; Invitrogen) was used in culture medium as mean of
selection up to 1000 μg/ml, until resistant cells were identiﬁed. After
selection, the cells were preserved in 200 μg/ml G-418 in standard
culture conditions. The luciferase-based promoter activity assay was
performed 48 h after transfection by ﬁreﬂy luciferase activity determina-
tion with the dual-luciferase reporter-assay system (Promega, Madison,
WI, USA) according to the manufacturer's protocol.2.2. Real time quantitative RT-PCR analysis
Total RNAs from samples were extracted using TRIzol reagent
(Invitrogen) according to the manufacturer's protocol, DNAseI-digested
and subjected to reverse transcription by Transcriptor High Fidelity
cDNA Synthesis Kit (Roche 05081955001) following manufacturer's
instructions. The total RNA from samples was measured by real-time
quantitative RT-PCR using PE ABI PRISM@ 7700 Sequence Detection
System (Perkin Elmer Corp./Applied Biosystems, Foster City, CA) and
SybrGreen method as described elsewhere [19]. The sequences of for-
ward and reverse primers were: 45A: 5′-CATCTATAATGGCTGAATTG
GAA-3′ and 5′-ATGAACTTTCCAACAAATGTTGTT-3′; APBB2 tot.: 5′-GAGC
CGAGGCGAGCG-3′ and 5′-TTCCATCCAGCAAATGTTTCTG-3′; APBB2 ex.
8: 5′-GTCACTTAGTTCTGTAACGCCATCTC-3′ and 5′-CCCCCATTCAGAACA
GCAA-3′; APP: 5′-TGGCCCTGGAGAACTACATCA3′ and 5′-CGCGGACATA
CTTCTTTAGCATATT-3′. For endogenous control, the expression of
Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) was examined.
The sequences for human GAPDH primers were 5′-GAAGGTGAAGGT
CGGAGTC-3′ and 5′-GAAGATGGTGATGGGATTTC-3′. The sequences for
human 5S rRNA primers were 5′-TACGGCCATACCACCCTGAA-3′ and
5′-GCGGTCTCCCATCCAAGTAC-3′ and for human U6 primers were
5′-AATTGGAACGATACAGAGAAGATTAGC-3′ and 5′-TATGGAACGCTTCA
CGAATTTG-3′. Relative transcript levels were determined from the
relative standard curve constructed from stock cDNA dilutions, and di-
vided by the target quantity of the calibrator following manufacturer's
instructions. For the determination of APBB2 variants RNA expression
in human post-mortem brain samples, we selected the appropriate
housekeeping gene [Topoisomerase (DNA) I, NM_003286.2] taking
advantage of geNorm Housekeeping Gene Selection Kit as described
elsewhere [30].
2.3. Human brain samples
Frontal and temporal cortices of 20 human post-mortem samples
were derived from P. Gambetti and Brain Bank (CaseWestern Reserve
University, Cleveland, OH, USA).
2.4. Aβ detection in HEK-293 permanently transfected cells
The amount of secreted Aβx-40 and Aβx-42 in the media of 45A
permanently transfected HEK-293 cells was evaluated by sandwich
ELISA (IBL, Gumna, Japan) as previously reported [20].
2.5. Western blot
Proteins were quantiﬁed using a commercial protein quantiﬁcation
kit (Protein Assay, Bio-Rad 500-0006) following the manufacturer's
instructions. The samples were subsequently analyzed by denaturing
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a
nitrocellulose membrane (Whatman, Inc.) as described elsewhere
[21,22]. The primary antibodies used were: rabbit polyclonal anti-APP,
C-terminal (A 8717 Sigma) (1:1000), anti-α-tubulin (T 5168 Sigma)
(1:2000), anti-APBB2 (ab64749 Abcam). Amyloid C-Terminal Frag-
ments Western blot analysis was performed by running protein sam-
ples on precast Tris-tricine gels in gradient 10–20% (Novex® 10–20%
Tris-Glycine Gel 1.0 mm, 12 well). The membranes were blocked by
an incubation of 1 h in phosphate-buffered saline Tween-20 containing
5% non-fat dried milk. The blot was incubated overnight with the pri-
mary antibody, rabbit polyclonal anti-APP, C-terminal (A 8717 Sigma)
(1:1000), diluted in 0.1%NaN3 in PBS. The densitometric analysis of pro-
tein bands was performed using the ImageJ software system.
2.6. Immunoﬂuorescence detection (confocal microscopy)
HEK-M and HEK-45A cells grown on slides, were ﬁxed with meth-
anol, washed 3 times with PBS and incubated with the different
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antigen-speciﬁc secondary antibodies (Alexa 488 or 568-conjugated, and
AMCA from Invitrogen Corporation, Carlsbad, CA, USA). Cells were then
mounted by Mowiol and analyzed on BioRad MRC 1024 ES confocal
microscope, equipped with a Nikon Eclipse TE 300 inverted microscope
with a 60× objective lens [23]. Antibodies for rabbit anti-APBB2 (Abcam
64749) were used at 1:100; Alexa Fluor® 568 and Alexa Fluor® 488
(Molecular Probes, Invitrogen Corporation, Carlsbad, CA, USA) were
used at 1:200.
2.7. Cell proliferation assays
A) We tested proliferation of HEK-M and HEK-45A cells, plating
25 × 104 cells/well in round-bottomed 24-well plates; cells were incu-
bating for 24 h and pulsed with [3H]-thymidine (0.3 μ Ci/500 μl/well)
(GE Healthcare, New York, NY) for the last 14 h. We calculated the
average proliferation rate by the thymidine uptake assay. B) For cell
counting studies, HEK-M and HEK-45A cells were seeded at 5 × 105
cells in 25-cm2 culture ﬂasks, incubated in standardmedium and count-
ed with a hemocytometer after 48 hours. C) Finally cell proliferation
was also assessed by xCELLigence RTCA MP System (Roche, Germany)
that monitors cellular events in real time by measuring electrical im-
pedance across interdigited gold micro-electrodes integrated on the
bottom of tissue culture plates. The impedance measurement provides
quantitative information about the biological status of the cells, includ-
ing cell number, viability, and morphology. Cell-sensor impedance is
expressed as an arbitrary unit called Cell Index (CI). In order to deter-
mine the Cell Index, cells were seeded into 100 μL of standard medium
in 96×microtiter plates (E-Plate-Roche, Germany). Background imped-
ance was determined using 50 μl of standard medium. Cell attachment,
spreading and proliferation were monitored every 15 min using the
xCELLigence system. Experimental results were performed using RTCA
Software 1.2 that calculated the population doubling by ﬁtting the
curve to an exponential equation. The number of cells seeded was dif-
ferent for every cell type: HEK-293 8 × 103 cells, HeLa 4 × 103 cells,
SH-SY5Y 7 × 103 cells and SKNBE2 104 cells.
2.8. Cell cycle analysis
The cell cycle was analyzed after 70/30% ethanol/water ﬁxation
permeabilization with 1% Nonidet P-40 (Sigma) and labeling with
propidium iodide (PI; Sigma). Samples were run on a FACSort
cytoﬂuorimeter (Becton Dickinson, Palo Alto, CA, USA), and cell cycle
analysis was performed by the ModFit LT 3.0 computer program (Verity
Software House, Topsham, ME, USA).
2.9. Apoptosis analysis
Apoptosis was analyzed by ﬂow cytometry, using Annexin V accor-
ding to themanufacturer's instructions Annexin V-APC (Apoptosis Detec-
tion Kit I; BD Biosciences, Oxford, UK; DAPI, Sigma–Aldrich, Milan, Italy).
HEK-M and HEK-45A cells were trypsinized, washed in PBS and
resuspended in serum free medium. Annexin V-APC and DAPI were
added to the cell preparations (105 cells) and incubated for 15 min
in the dark at room temperature [24]. Samples were analyzed using a
Cyan ADP cytoﬂuorimeter (Beckman-Coulter, Brea CA, USA). For each
sample, 20,000 events were acquired. The data were analyzed using
Summit 4.3.1 software (Beckman-Coulter, USA).
2.10. cDNA synthesis and real time-PCR array
The cDNA for each RNA sample was obtained using RT2 First Strand
kit (SABiosciences Corporation, QIAGEN Company, Frederick, MD)
according to the manufacturer's instructions. Brieﬂy, after genomic
DNA elimination, the reverse transcription reaction was performed at
42 °C for 15 min and then heated at 95 °C for 5 min to inactivate theenzyme. The cDNA was mixed with RT2 SYBR green/ROX qPCR master
mix (SABiosciences Corporation) and 25 μl aliquots were loaded into
each well of the RT2 Proﬁler PCR Array (SABiosciences Corporation,
Cat. No. PAHS-020 SABiosciences). The PCR array was designed to
study the proﬁle of 84 human cell-cycle-related genes. PCR array
experiments were performed on an Eppendorf Realplex4 epgradient S
Mastercycler®. Conditions for ampliﬁcation were as follows: 1 cycle of
10 min at 95 °C followed by 40 cycles of 15 s at 95 °C and 1 min at
60 °C. The PCR array data were analyzed by PCR Array Data Analysis
web-based software (SABiosciences Corporation).2.11. Colony forming assay
HEK-M and HEK-45A cells were seeded at 400 cells in 60 mm dish,
3 dishes per dose, for the determination of cell survival measured as
colony forming ability. After 8–10 days, the dishes were ﬁxed and col-
onies counted. Adriamycin (Ebewe Italia, Rome, Italy) was diluted in
PBS−, like MMS (Fluka); cells were UV-C irradiated in the absence
of medium with a germicidal lamp emitting 254-nm, as monitored
by a UVX digital radiometer (Ultraviolet Products, San Gabriel, CA).
Adriamycin was tested at doses 0.01 μM, 0.05 μM and 0.1 μM; MMS
was tested at doses 0.05 mM, 0.1 mM and 0.5 mM; UV doses were
5 J/m2, 10 J/m2 and 20 J/m2.2.12. Cytotoxicity assay in real-time
Cytotoxicity assay was performed by xCELLigence RTCA MP Sys-
tem (Roche, Germany). 104 cells were plated in E-plate 16; for each
treatment, cells were seeded in triplicate. 24 h after seeding, cells
were treated with adriamycin (0.5 μM e 5 μM) and MMS (100 μM e
1 mM) and the CI was monitored every 30 min up to the end of the
experiment (140 h).2.13. MN assay
The day before treatment, cells were seeded in 35-mm dishes with
coverslips. Cells were cultured at densities of 3 × 105 cells/coverslip,
using conditions ensuring that cells were actively growing after
24 h treatment for adriamycin, 1 h treatment for MMS and a time
variable for UV, depending from the intensity of the lamp. At the ap-
propriate harvest time, cells were rinsed and exposed to a hypotonic
shock in situ using Iskandar solution (0.9% NaCl/75 mM KCl; 9:1).
Cells were then ﬁxed with MeOH/HOAc (3:1) and stained with Giemsa.
All slides including those of positive and solvent controls were coded
before analysis and scored blindly for the evaluation of MN by two inde-
pendent observers. The criteria used for identifying MN fulﬁl those
recommended by the HUMNwork [25]: (1) area b1/3 the main nucleus
area; (2) no overlapping with the nucleus (distinct borders); and
(3) same aspect as the chromatin. Adriamycin was tested at doses
0.01 μM and 0.025 μM; MMS was tested at doses 0.05 mM and
0.1 mM; UV doses were 5 J/m2 and 10 J/m2.2.14. Methylcellulose colony formation assay
Clonogenic assay was performed using a methylcellulose medium
consisting of DMEM for HEK-293 cells and RPMI 1640 for SKNBE2 cells
with 0.9% methylcellulose (Methocult H4100; StemCell Technologies,
Vancouver, BC, Canada), 10% FBS, 100 U/ml penicillin/streptomycin and
2 mM L-glutamine. Cells were plated at a density of 400 cells in 2 ml
volume of methylcellulose medium in humidiﬁed 6-well plates. For
each assay, suspension cells were plated in triplicate. Colonies were
counted at 12 days for HEK-293 cells and at 14 days for SKNBE2 cells
after plating.
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Cellmigrationwas analyzed by the new technique of real-timemigra-
tionmonitoring using the CIM-Plate 16 and xCELLigence SystemRTCADP
Instrument (Roche). The day before migration assay, cells were plated in
starvation medium (medium with FBS 0.5%). After 24 h, 4 × 104 cells,
resuspended in 100 μl of serum-free medium, were seeded in the upper
chamber of a CIM-Plate 16. The upper chamber was then placed on
the lower chamber of the CIM-Plate 16 containing growth medium
supplemented with 20% FBS as an attractant, or without FBS (negative
control). Time-dependent cell migration was monitored over a period
of up to 18 h, and experimental results were analyzed using RTCA Soft-
ware 1.2 considering the interval of 0–6 h.
2.16. Cell adhesion assay
This protocol was adapted from [26]. Cells were plated at 1,5 × 105
cells/well in a 24-well tissue culture plate; 3 h after cell plating, the
multiwell platewas centrifuged twice in inverted position (well bottom
placed up in a swing-out rotor) at 1000 rpm for 30 s. The cells still
adherent to the wells were then ﬁxed in 3.7% paraformaldehyde in
PBS, stained with methylene blue and counted (each well was divided
in quadrants and 3 quadrants/well were counted). Each value repre-
sents the mean ± SD of three independent wells.
2.17. Immunoﬂuorescence
For morphological examination, HEK-M and 45A cells were seeded
in l-Slide eight-well (Ibidi GmbH, Martinsried, Germany) in standard
medium. After 24 h, the cells were ﬁxed in pre-warmed (37 °C) 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 20 min at
37 °C, permeabilized with 0.1% Triton X-100 in PBS for 5 min, and
blocked for 1 h in 2% bovine serumalbumin/PBS. Then the cells were in-
cubated with rabbit anti-α tubulin (1:200 dilution; Abcam, Cambridge,
UK) in PBS–bovine serum albumin 1% for 24 h at room temperature.
Following three rinses in PBS of 10 min each, cells were incubated
with TRITC-labelled secondary antibody [anti-rabbit IgG (H + L) 1:75
dilution; Jackson Immunoresearch Laboratories, Inc. West Grove, PA,
USA] in PBS–bovine serum albumin 1% for 1 h at room temperature.
The incubation was stopped by three 10 min rinses with PBS. Cells
were stained with DAPI (100 μg/ml; Invitrogen, Carlsbad, CA, USA) in
H2O for 5 min. Fluorescent images were captured with a Zeiss Axiovert
200 M inverted microscope (Zeiss, Jena, Germany), equipped with
Apotome technology, at a ﬁnal magniﬁcation of 63×, and processed
by using Zeiss AxioVision 4.8 software (Zeiss).
2.18. Mice
Homozygous NOD-SCID (NOD.CB17-Prkdcscid) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, MA). Mice were
used between 5 and 9 weeks of age. All animals were bred and
maintained at the institution's animal facility of the National Institute
for Cancer Research, Genova, Italy. The care and the use of the animals
were in compliance with laws of the Italian Ministry of Health and the
guidelines of the European Community.
2.19. In vivo tumorigenicity assay
SKNBE2-Mock (hereafter referred to as SKNBE2-M), SKNBE2-45A,
HEK-M and HEK-45A cell suspensions (3 × 106 cells in PBS) were sub-
cutaneously injected into 4 NOD/SCID mice groups composed of 5 mice
each.Micewere observedweekly for the appearance of tumors at injec-
tion sites; tumor sizewasmeasured dailywith calipers in all groups and
these experimental data have been represented by a progression tumor
graph. To calculate the tumor development function by the polynomial
interpolation, we used the average of the daily measures when eachmouse had the tumor mass. For SKNBE2-45A mice, we calculated the
weighted mean of the daily measures as follows: to mice #1, #2, #3
and #4, characterized by a similar growth progression, we attributed a
relative weight value of 22.5%, with respect to the mouse #5 to which
we attributed a relative weight value of 10%. This method has been
used to reduce the effect of the ﬁfth mouse, whose growth progression
in terms of time and tumor size was atypical. For each group we also
derived the averaged progression rate by the linear regression.
2.20. Statistical analysis
Statistical signiﬁcance of observed differences among different exper-
imental groups was calculated using a two-tailed t-test. In the ﬁgures,
* and ** indicate statistical signiﬁcance at P b 0.05 and 0.01, respectively.
3. Results
3.1. 45A is a novel snRNA-like transcription unit
By bioinformatic search for Proximal Sequence Element (PSE)/TATA-
containing snRNA-like elements in the human genome, we identiﬁed a
novel transcription unit that synthesize a 78 nt long transcript (hereafter
referred to as 45A RNA) [16]. To gain hints onto its transcriptional activity
in different cells and/or conditions we fused 45A pol III type 3 promoter
to a luciferase silencer hairpin (pSHAG-45A, hereafter referred to as pS-
45A). In this condition, if the 45A promoter is active in a speciﬁc cell
line, the transcription of the hairpin drives the post-transcriptional silenc-
ing of a co-transfected luciferase cDNA and, ultimately, the decrease of
luciferase signal; on the contrary, unaltered luminescent signal would in-
dicate that luciferase is not silenced and thus the 45A promoter is not ac-
tively transcribed in the cell line tested. As shown in Fig. 1A,wedetected a
42% and a 46% decrease of luciferase emission 48 h after co-transfection
of pS-45A with a plasmid expressing luciferase (pGL3), in HEK-293 and
SKNBE2 cells respectively, demonstrating efﬁcient transcription of the
hairpin driven by 45A promoter in both the cell types. As positive con-
trols, constructs harboring the same luciferase-silencing hairpin under
the control of two well assessed Pol III type 3 promoters (those of
the U6 RNA gene, coding for an RNA component of the spliceosome,
and the H1 gene, coding for the RNA component of RNAse P) led to a
signiﬁcant luminescence reduction whereas a negative control (NP,
a promoter-less hairpin) did not alter luciferase signal (Fig. 1A). Altogeth-
er, these results demonstrate that 45A transcription unit is active both
HEK-293 and SKNBE2 cell lines.
3.2. The expression of 45A promotes APBB2 splicing perturbation
Since 45A transcription unit maps within intron 1 of APBB2 in anti-
sense conﬁguration (see Fig. S1) and considering that this protein is
subjected to alternative splicing that generates alternative protein forms
[as reported by AceView database (http://www.ncbi.nlm.nih.gov/IEB/
Research/Acembly/)] (Fig. 1B), we hypothesized that, similarly to other
pol III-transcribedncRNAs recently characterized byus [17–19], 45A tran-
scription might perturb APBB2 pre-mRNA maturation leading to the
synthesis of alternatively spliced protein forms.
To test this hypothesis we generated a cell line stably overexpressing
45A RNA driven by its endogenous promoter. In order to better visualize
the effects of 45A expression, we choose cells expressing the lowest level
of endogenous 45A [HEK-293 cells (see Fig. 1F)] to be equipped with
extra-copies of 45A transcription unit together with a GFP reporter
cassette (hereafter referred to as HEK-45A cell line). As control, HEK-
293-Mock cell line (hereafter referred to as HEK-M) was obtained inte-
grating an empty pEGFP-N1 plasmid vector in HEK-293 genome. After
clonal selection, the expression level of 45A was measured by Real Time
RT-PCR in both the transgenic cell lines. HEK-45A cells express
43.14-fold increased level of 45A ncRNA with respect to HEK-M cells
(Fig. 1C). Similar levels of overexpression of 45A ncRNA were detected
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Fig. 1. The increased expression of 45A ncRNA promotes APBB2 splicing shift. A) Promoter activity transfection assay in HEK-293 and SKNBE2 cells. Transcription of a speciﬁc
luciferase-silencing hairpin was driven by 45A PSE-dependent promoter. The promoter region encompasses the putative pol III type 3 regulatory regions (TATA box and PSE).
pS-NP, pShag-No promoter negative control; pS-U6, pShag-U6 positive control; pS-45A, pSHAG-45A; pS-H1, pSHAG-H1 positive control. B) Schematic view of the three splicing
variants (a, b and c) of APBB2 protein [variants a and b have an additive exon (the eighth) with respect to the c; variant a has the sixth intron longer than variant b and variant
c (see Aceview annotations at www.ncbi.nlm.nih.gov/IEB/Research/Acembly)]. The location of primers, relative to 45A RNA is reported by darts. C) Expression of 45A, 5S rRNA
and U6 snRNA in HEK-M and HEK-45A permanently transfected cell lines. Inset: ampliﬁcation product dissociation curve unambiguously distinguishes the RNA of interest by
peaks at speciﬁc temperatures. D) Real-time RT-PCR quantitative determination of APBB2 splicing variants and relative ratio in HEK-M and HEK-45A permanently transfected
cell lines (Inset: the ampliﬁcation product dissociation curve unambiguously distinguishes the RNA of interest by peaks at speciﬁc temperatures). E) 45A RNA expression and
APBB2 spice variants ratio in HEK293 cells overexpressing Anti-45A RNA. F) 45A expression and determination of APBB2 splicing variants and relative ratio in cells of different
origin, as determined by real-time RT-PCR.
1515I. Penna et al. / Biochimica et Biophysica Acta 1833 (2013) 1511–1526also in two independently isolated clones (data not shown). In order to
assess the speciﬁcity of 45A expression the level of synthesis of two
unrelated pol III-transcribed ncRNAs such as U6 and 5S rRNA was mea-
sured in the two cell lines. Results showed that the expression level of
these transcripts is stable if not slightly diminished in HEK-45A cells,
demonstrating that overexpression of 45A RNA in these cells isgene-speciﬁc and not due to a generic enhancement of RNA polymerase
III transcriptional activity (Fig. 1C). Altogether these data demonstrate
that HEK-45A cells constitute an adequate in vitro model to study the
effects of 45A overexpression.
To investigate possible differences in APBB2 splicing occurring in
HEK-45A cells, we measured alternative APBB2 mRNA levels by splice
1516 I. Penna et al. / Biochimica et Biophysica Acta 1833 (2013) 1511–1526variant-speciﬁc Real Time RT-PCR. Indeed, three alternatively spliced
APBB2 protein forms (derived by mRNAs endowed with both 5′ and
3′ untranslated regions) have been so far predicted [namely variants
“a”, “b”, “c” in AceView (www.ncbi.nlm.nih.gov/IEB/Research/Acembly/
av.cgi?exdb=AceView&db=36a&term=apbb2&submit=Go)].
These isoforms are not clearly discernible in SDS-PAGE as they only differ
by about 2.2 KD. To overcome this limitation we used Real Time RT-PCR
reactions based on two different pairs of oligos: oligos α (that amplify
all the splice variants “a”, “b” and “c”) and oligos β [(that amplify exclu-
sively those splice variants that enclose the 63 bp-long exon 8 (“a” and
“b”)]. Results, expressed as oligos β vs. oligos α ampliﬁed mRNA ratio,
showed that HEK-45A cells stably produce a 1.5-fold increased β vs. α
splice variant ratio as a consequence of decreased expression of variant
“c” with respect to exon 8-containing variants (“a” and “b”) (Fig. 1D).
Thus, these data demonstrate that 45A-overexpressing cells synthesize
increased amounts of exon 8-containing APBB2 splice forms (var. a, b)
in comparison to the exon 8-missing one (var. c). Although the additional
63 bp-long exon 8 (Q92870) encodes for 21 a.a.most ofwhich are hydro-
phobic (52.4%) it has not been possible yet to discern its role in APBB2
function. To demonstrate the effective occurrence the different APBB2
variants in normal human brains, RT-PCR analysis was performed on
mRNA isolated from 20 human brain post-mortem samples. The re-
sults, expressed as the average of the single samples values, showed
that, although an expected variability among the different samples
was detected, a signiﬁcant amount of APBB2 variant “c” was
detected, reaching a level comparable to HEK-Mock cells (data not
shown).
Next, we further demonstrated that the perturbation of the ratio
among different splicing variants was directly triggered by the syn-
thesis of 45A ncRNA measuring the ratio in HEK293-Anti45A cells, a
transgenic cell line harboring a permanently an additional transcrip-
tional unit expressing 45A in antisense (AS) conﬁguration
(Anti-45A). Results showed that in this condition the decrease of
the amount of 45A ncRNA is accompanied by reduction of APBB2
exon8/total variants ratio (Fig. 1E).
To further support the hypothesis that increased synthesis of
splice variants a and b is driven by the overexpression of 45A
ncRNA, we measured the levels of (1) 45A ncRNA, (2) APBB2 variants
“a” + “b” + “c”, (3) APBB2 variants “a” + “b”, and (4) the ratio
between exon 8-containing and exon 8-missing protein forms in
ﬁve different cell lines, namely HEK-293, HeLa, LoVo, SH-SY5Y and
SKNBE2. As shown in Fig. 1F, the synthesis of 45A ncRNA in human
cells of different origin is modulated in a cell type-speciﬁc manner
and roughly overlaps with the increase of the synthesis of the exon
8-containing mRNA variants.
Although the comprehensive panel of possible APBB2 splice
variants include several other members here not evaluated, our
ﬁndings support the hypothesis that 45A ncRNA synthesis drives
a splicing shift of APBB2 leading to the expression of exon
8-containing protein forms (variants “a” and “b”). Therefore, in
this context we hypothesized that the balance among different
protein variants with peculiar functional traits might be at the
base of cell physiology alterations.
3.3. 45A overexpression inhibits Aβ secretion, increases Aβ-x42/Aβ-x40
ratio and alters APBB2 subcellular localization
It has been demonstrated that FE65 overexpression increases Aβ
secretion, through the enhancement of APP C-terminal fragments
processing and the release of AICD induced by a higher γ-secretase
cleavage. This prompted us to test whether the observed alteration of
the relative amounts of different APBB2 variants may affect Aβ release.
To this aimwemeasured, by sandwich ELISA, the amount of Aβ-x40 and
Aβ-x42 released by HEK-M and HEK-45A cells. We found a signiﬁcant
reduction of the total amount of released β−amyloid by 45A-
overexpressing cells (39.22% in comparison to HEK-M). This effectwas mainly associated to Aβ-x40 release (42%) rather than Aβ-x42,
whose secretion was modestly affected (16%). Therefore, this re-
sult shows that, besides a general inhibition of amyloid release,
45A overexpression, driving to a 44% increased Aβ-x42/Aβ-x40
ratio, may generate conditions favorable to Aβ aggregation
(Fig. 2A).
In order tomechanistically strengthen the link between the perturba-
tion of the relative amount of APBB2 protein variants (triggered by the
overexpression of 45A RNA) and Aβ release we transfected HEK293
cells with a plasmid construct encoding for APBB2 protein variant “a”
thus mimicking the condition driven by 45A-overexpression. We then
measured the amount of Aβ−x40 released in the medium 48 h
after transfection evidencing a 42% decrease of Aβ released
in cells overexpressing APBB2 variant “a” with respected to
pMock-transfected cells (Fig. 2B). Again, this ﬁnding demonstrates
that an increase of the relative fraction of APBB2 variant “a” leads to
a decrease of Aβ-x40 release.
Next, to assess whether 45A RNA overexpression leads speciﬁcally to
a decrease of Aβ release, or rather it inhibits also the non-amyloidogenic
pathway of APP processing we measured the amount of the C-terminal
fragment C83 (CTF83) in HEK-45A and/or in HEK-M control cells.
We found that the level of C83 is markedly reduced by 45A RNA over-
expression (−44% as resulting from the average of three independent
determinations) according with a global reduction of APP processing
driven by 45A-overexpression (Fig. 2C).
To investigate the molecular mechanism mediating these effects,
we tested possible variations of APP synthesis in HEK-45A cells at
mRNA and at protein level. We show that the overexpression of 45A
RNA does not alter the amount of APP suitable for processing, neither
at mRNA nor at protein level (Fig. 2D). The data exclude that the re-
duced release of amyloid β is due to the inhibition of APP synthesis
but rather suggest a direct effect on its processing. We thus
addressed the hypothesis that the alternative forms of APBB2
might have a different subcellular localization with marked effects
on their interaction with APP. As previously reported by others
[27] this would reduce the residence time of the complex APBB2:
APP that, as a consequence, would less efﬁciently expose APP to
γ-secretase cleavage.
To test this hypothesiswe took advantage of anAPBB2-speciﬁc antise-
rum in order to possibly identify changes in the subcellular localization of
APBB2 in 45A overexpressing cells. As shown in Fig. 2E, we found by con-
focal microscopy analysis, an extensive cellular and perinuclear localiza-
tion of APBB2 in Mock and 45A-overexpressing cells. Conversely, while
in the nucleus of Mock cells a barely detectable APBB2 signal was
observed, a signiﬁcant APBB2 nuclear localization was detected in 45A
overexpressing cells (Fig. 2E), suggesting a different sorting within the
cell of the alternative variants of APBB2.
In the light of the above results, we concluded that the alternative
forms of APBB2 induced by the overexpression of 45A RNA, are differ-
entially localized within the cell and that this phenomenonmay affect
APP processing.
3.4. 45A-driven cascade of reactions affects cell proliferation control
The increased nuclear localization of APBB2 and the previously
reported alteration of cell proliferation rate by FE65 and relatedproteins
overexpression [13], induced us to hypothesize that the message
brought to the nucleus by APBB2 might be ampliﬁed overexpressing
45A RNA. More speciﬁcally, we postulated an increase of the cell prolif-
eration rate in HEK-45A cells carrying higher relative amounts of APBB2
alternative forms vs. the canonical protein variant. Indeed, it has been
previously demonstrated that overexpression of the canonical variants
of FE65 proteins restricts cell proliferation in ﬁbroblasts and that in par-
ticular, APBB2 negatively modulates proliferation in PC12 cells through
a panel of genes that still remains to be completed [13]. In this context,
we hypothesized an increased cell proliferation rate in HEK-45A cells in
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1517I. Penna et al. / Biochimica et Biophysica Acta 1833 (2013) 1511–1526which the variant “c” of APBB2 is diminished. To test our hypothesis we
measured the proliferation rate of HEK-M and HEK-45A cells by di-
rect determination of population doubling time (PD) and [3H]-thy-
midine incorporation. As expected, we found a signiﬁcant increase
of HEK-45A proliferation (1.58-fold) in comparison to HEK-M,
with a PD of 24 h in HEK-45A cells and of 30 h in HEK-M cells
(Fig. 3A).
This result was validated analyzing cells of different origin: HEK-293
(epithelial), HeLa (epithelial), SH-SY5Y (non-Myc-N ampliﬁed Neuro-
blastoma) and SKNBE2 (Myc-N ampliﬁed Neuroblastoma), permanent-
ly transfected with a plasmid harboring 45A transcription unit under
the control of its endogenous promoter. As resulting by xCELLigence de-
tection system, the stable overexpression of 45A ncRNA enhanced the
proliferation rate in all the cell lines tested, evidencing that 45A RNA
is a general regulator of intracellular pathways involved in the control
of cell proliferation (Fig. 3B). Similar results were obtained in SKNBE2/
45A-overexpressing cells (data not shown). Altogether these results
demonstrate again an inhibitory effect on cell cycle progression exerted
by the canonical APBB2 splice variant “a” thus supporting a direct role
on cell proliferation control of 45A ncRNA through an APBB2 splicing var-
iant shift.
In order to assess whether the effects of 45A RNA expression on cell
proliferation might be also extended to the cell tumorigenic potential,we measured by real time RT-PCR the expression of 45A RNA in two
SKNBE2-derived cell lines (S1 and S2) engineered in order to exhibit dif-
ferent levels of malignancy [14] (see Castelnuovo et al.). Results showed
that 45A is predominantly expressed in the more malignant S2 cells
whereas its amount is 2.7-fold decreased in the more differentiated,
slightlymalignant S1 cells (Fig. 3C). In addition,we compared the expres-
sion of 45A RNA in two neuroblastoma cell lines with different tumori-
genic potential, such as the Myc-N-ampliﬁed SKNBE2 cells vs. the
non-Myc-N-ampliﬁed SH-SY5Y cells evidencing again a direct correlation
between the expression of 45A and the oncogenic potential of the cell
(Fig. 3D).
Next, to characterize the mechanism by which 45A affects cell prolif-
eration,we analyzedHEK-45A andHEK-M cell cycle distribution by FACS.
Results showed only barely detectable differences between the two cell
lines as far as G0/G1 and S phases, whereas the percentage of cells in
G2/M (6.45%) was markedly diminished (4.46%) in HEK-45A cell line
(Fig. 3E). This scenario suggests that a restriction of G2 and G2/M transi-
tion is induced in these cells. In order to assess whether the augmented
cell proliferation rate is accompanied by higher apoptotic rate, we
analyzed these cells by Annexin V-APC FACS and found that the percent-
age of viable vs. apoptotic cells is not affected by 45A overexpression
(Fig. 3F). Altogether these results demonstrate a direct control of cell pro-
liferationmediated by 45A ncRNA and supporting the direct involvement
1518 I. Penna et al. / Biochimica et Biophysica Acta 1833 (2013) 1511–1526of APBB2 canonical variants in cell cycle arrest previously documented by
others [13]. Indeed, these data demonstrate that the down-regulation of
APBB2 isoforms, driven by 45A ncRNA, generates the opposite effect of
the overexpression and that, unexpectedly, this process can be regulated
by an upstream pol III-dependent transcript.E
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1519I. Penna et al. / Biochimica et Biophysica Acta 1833 (2013) 1511–1526modulation of nuclear gene expression [13], we hypothesized that
the expression of this ncRNA (and the consequent alteration of the
relative abundance of APBB2 isoforms) might modulate the expression
of genes involved in cell cycle control. To test this hypothesis we mea-
sured by cell cycle-speciﬁc real time low density array (Human CellFig. 3. Effects of 45A ncRNA on cellular proliferation. A) [3H]-thymidine incorporation assay and p
lines. B) Cell Index (CI) curves of cellular proliferation of cells of different originMock and 45A perm
time scale bar (in hour) for SH-SY5Y is due to their different proliferation rate. C) Determination
different tumorigenic potential D) and in twodifferent neuroblastoma cell lines. E)Distribution in c
F) Diagrams of APC-Annexin V/DAPI ﬂowcytometry of HEK-293MandHEK-293-45A cells. The low
APC-Annexin V binding. The upper right quadrants (R3) contain the nonviable, necrotic cells, posit
the apoptotic cells, APC-Annexin V positive and DAPI negative.Cycle RT2 Proﬁler™ PCR Array) the simultaneous expression of 84
genes involved in cell cycle control, in HEK-45A and HEK-M cells. By
arbitrarily imposing appropriate cut-off values (+22.5 b y b +30
gene expression for the up-regulated genes and −2.29 b y b −1
gene expression for down-regulated genes), we found 9 genes whoseopulation doubling (PD) time of HEK-293M and HEK-293-45A permanently transfected cell
anently transfected obtained by the xCELLigence RTCADP Instrument (Roche). The peculiar
by Real Time RT-PCR of the expression of 45A RNA in two transgenic SKNBE2 cell lines with
ell cycle phases ofHEK-293MandHEK29345A cells, as determined by PI-based FACS analysis.
er left quadrants of each panel show the viable cells, which excludeDAPI and are negative for
ive for APC-Annexin V binding and for DAPI uptake. The lower right quadrants (R5) represent
Fig. 5. 45A ncRNA affects short-term response to genotoxic stress. A) Percentage of colony survival of HEK-293M andHEK-29345Apermanently transfected cell lines to adriamycin (Adr),
Methyl methanesulfonate (MMS) and UV light treatments. B) Real Time cytotoxicity of HEK-293-M and HEK-29345A to Adr,MMS and UVmonitored by the xCELLigence RTCADP Instru-
ment (Roche). C)Micronuclei (MN) induced in HEK-293-M and HEK-29345A cells before and after Adr, MMS and UV radiation treatments. D)Multinucleated cells (MultiN) HEK-293-M
and HEK-293-45A before and after Adr, MMS and UV radiation treatments. E) An example of the microscope evaluation of MN (indicated by arrows) and MultiN cells (arrowhead).
1520 I. Penna et al. / Biochimica et Biophysica Acta 1833 (2013) 1511–1526expression is signiﬁcantly modulated by 45A overexpression (Fig. 4).
Interestingly, in HEK-45A cells, up-regulation is observed for those
genes that promote cell proliferation, whereas down-regulated genesFig. 6. 45A ncRNA affects short-term response to cell cycle progression. PI-based FACS anal
treatments. Full bars: Mock cells; striped bars: 45A cells. U: untreated sample; T: treated splay important roles in differentiation and in cell cycle arrest in
response to DNA damage (Fig. 4). Therefore, this cell cycle-speciﬁc
gene expression analysis could draw a novel scenario where theysis, before and after A) adriamycin, B) methyl methanesulfonate and C) UV radiation
ample.
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1522 I. Penna et al. / Biochimica et Biophysica Acta 1833 (2013) 1511–1526induction of cell cycle proliferation exerted by 45A ncRNA is mediated
not only by the promotion of cell cycle progression but also by the con-
comitant inhibition of DNA damage response processes.
3.6. The overexpression of 45A RNA affects short-term response to genotoxic
stress and cell cycle progression
Considering together the increased proliferation rate and the down-
regulation of genes involved in DNA repair and cell cycle checkpoint acti-
vation in response to DNA damage (i.e. GADD45A and HUS1), we
hypothesized that the high proliferation activity of these cells might be
associated to increased susceptibility to genotoxic damage. To test this hy-
pothesis we investigated the response of Mock and 45A cells to the treat-
ment with chemical and/or physical agents known to induce speciﬁc DNA
damages resulting in the activation of different DNA repair pathways.
To this aim cells were treated with adriamycin, methyl metha-
nesulfonate (MMS) and ultraviolet radiation (UV) and cell viability was
assessed by colony forming ability and xCELLigence RTCA. Survival curves
obtained through the colony forming ability assay did not reveal signiﬁ-
cant differences between the two cell lines (Fig. 5A). However, the real
time monitoring of cell proliferation following adriamycin and MMS
exposure revealed a higher sensitivity of 45A than Mock cells to these
agents (Fig. 5B). These differences may rely on the ability of the
xCELLigence system to measure short-term effects of the treatment that
may not be detectable with the colony assay. Therefore, to better investi-
gate the inﬂuence of 45A-overexpression on DNA damage response, the
induction of micronuclei (MN) was determined. MN assay has emerged
as one of the preferred methods for assessing chromosome damage
[28,29]. MN are known to formwhen cells enter mitosis with unresolved
chromosomal damage and can only be expressed in cells that complete
nuclear division.
Cells were treated with 0.01 μM and 0.025 μM adriamycin [a dou-
ble strand break (DSB) inducer that can activate the repair] and the
generation of micronuclei in Mock and 45A cell populations was mea-
sured. In HEK-M cells a dose-dependent increase of MN was detected,
whereas at high dosages of adriamycin HEK-45A cells generate a re-
duced number of micronuclei (Fig. 5C). Accordingly, treatment with
MMS, an alkylating agent known to induce single strand breaks and
chromosomal aberrations and efﬁciently activate the base excision
repair (BER) pathway, increased MN formation in HEK-M but only
slightly modiﬁed their occurrence in HEK-45A cells, although this var-
iation was not statistically signiﬁcant (Fig. 5C). The treatment of the
same cells with UV, a physical agent activating the nucleotide exci-
sion repair (NER), did not affect MN formation both in Mock and in
45A cells (Fig. 5C).
In order to better clarify the effects of the genotoxic agents on
45A-overexpressing cells, we also tested the possible differential sus-
ceptibility to adriamycin, MMS and UV also in terms of generation of
multinucleated cells (Fig. 5D). Results showed that although the treat-
mentwith adriamycin induces an apparent reduction ofmultinucleated
cells in Mock cells, the induction of multinucleated 45A-cells was not
affected by the treatment. Mock cells treated with MMS showed a
dose-dependent increase of multinucleated cells that was not observed
in 45A cells. Last, we analyzed the effects of UV treatment on the two
cell populations. We found that in Mock sample multinucleated
cells increase proportionally to the stimulus, whereas 45A cells form
multinucleated cells only at the highest dose of UV. A graphical repre-
sentation together with the microscopic evaluation of these results at
the most critical dosages of the experiments is reported in Figs. 5D
and E.
Altogether these results suggest that the 45A-dependent increase of
cell proliferation rate is not accompanied by a signiﬁcant increase ofMN
and multinucleated cells. Since cytotoxicity experiments showed a
higher sensitivity of 45A cells toward adriamycin and MMS, the lack
of MN induction in 45A cells can be related to the consequences of
these exposures on cell cycle progression soon after the treatments.Alterations of cell cycle progression are associated to treatment
with genotoxic agents. Thus, we investigated whether the expression
of 45A ncRNA affected the distribution among cell cycle phases fol-
lowing adriamycin, MMS and UV treatments.
To this aimwe focused on the most efﬁcient dosages of treatments
previously observed and measured by FACS analysis potential
changes of speciﬁc cell cycle phases induced by the agents (Fig. 6).
We found that if normalized to the reactions induced in untreated
cells, the treatment with 0.025 μM adriamycin of 45A cells induces a
strong decrease of the percentage of cells in G2/M and a roughly com-
plementary increase of the population in S phase whereas in Mock
cells this effect was undetected (Fig. 6A). Similarly, the treatment
with MMS of 45A cells increases the S phase reducing concomitantly
G0/G1. Conversely, a signiﬁcant decrease of the percentage of cells in
G2/M was observed both in Mock and in 45A cells (Fig. 6B). Since UV
treatment determine a slow down of the cell cycle evident as a high
fraction of cells in S phase and a reduction of cells inG2/Mphase,wemea-
sured the cell cycle distribution ofMock and 45A cells following UV treat-
ment. We found that in 45A-overexpressing cells, similarly to the Mock
cells, the S phase fraction is increased but 45A-overexpressing cells
partially escape the block of cell cycle maintaining an increased fraction
of cells in G2/M not found in Mock cells. This peculiar cell cycle distribu-
tion is balanced by the concomitant reduction of the G0/G1 cell phase in
Mock and even more in 45A cells.
These results indicate that the expression of 45A signiﬁcantly affects
the progression through the cell cycle following exposure to different
DNA damaging agents. However, while after adriamycin and MMS
treatments, 45A cells show a higher percentage of S-phase cells than
the Mock cells, following UV irradiation the 45A-overexpressing cells
overcome the cell cycle blockage observed inMock cells after UV irradi-
ation, reducing the G0/G1 phase (Fig. 6C). A possible explanation of the
above results is that following UV irradiation the up-regulation of cell
cycle genes and the down regulation of GADD45A observed in
45A-overexpressing cells would speed up the progression through the
cell cycle. Nevertheless, this response did not inﬂuence genotoxic dam-
age formation (detected asMNandmultinucleated cells), suggesting that
the NER pathway was likely not affected by 45A-overexpression. On the
other hand, treatment of 45A cells with adriamycin and MMS likely acti-
vated other DNA damage response pathways that slow down
DNA replication and, consequently, did not allow an exhaustive MN
expression.
3.7. 45A increases malignant potential of neuroblastoma cells in vitro
and in vivo
Since 45A RNA induces marked effects on cell proliferation and
on the capability of the cells to respond to genotoxic damages, we hy-
pothesized that it might also affect biochemical pathways involved in
neoplastic transformation which might accompany a forced increase
of cell proliferation induced by 45A RNA overexpression. To test this
hypothesis we ﬁrst evaluated the colony forming potential in non-
adhesive conditions (methylcellulose) of both normal (HEK-293) and
tumoral (SKNBE2) cells. The overexpression of 45A in SKNBE2 neuro-
blastoma cells signiﬁcantly increases the colony forming potential,
supporting a possible enhancement of cancer malignancy (Fig. 7A).
On the contrary, the stable overexpression of 45A RNA in HEK-293
cells does not increase the colony forming capacity suggesting that
although 45A ncRNA promotes cell proliferation in both the cell lines,
it might favor malignant potential in a cell type-speciﬁc manner in
vitro (Fig. 7B).
Besides the quantitative evaluation of the colony forming potential,
the qualitative characteristics of 45A-overexpressing cells provided us
with indications of their possible acquisition of alteredmigratory capac-
ity. Indeed, while HEK-M cells form rounded colonies in adherent con-
ditions, 45A cells show less organized clusters of cells that tend to
disperse throughout the surrounding space, according with the
Fig. 7. Increase of adhesiveness and migratory ability in 45A-overexpressing cells. A) Capacity of SKNBE2 and B) HEK-293 cells to form colonies in methylcellulose. C) Morphological
analysis of colonies grown in adhesive condition of HEK-293-M and HEK-293-45A cells. Right panels: GFP-positive colonies, as shown in the overlay picture. Left panels: transmitted
light picture. D) Migration assay: using the xCELLigence RTCA DP instrument (Roche), migratory capability of HEK-293-M and HEK-29345A cells has been quantiﬁed by the slope of
the migration curve calculated by the RTCA 1.2 Software. E) Adhesion properties of HEK-293M and HEK-29345A permanently transfected cell lines. Adherent cells were stained by
methylene blue staining (lower panel) and quantiﬁed by calculating the mean of cells counted in 3 independent wells (upper panel). F) Morphological analysis of HEK-293-M and
HEK-29345A permanently transfected cell lines by ApoTome Microscope Technique from Carl Zeiss. Blue = DAPI, green = GFP, red = anti αtubulin.
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this aspectwemeasured the changes in themigratory potential of HEK-
45A cells by two additional approaches, the xCELLigencemigratory andthe methylene blue cell adhesion assays. Both the assays showed that
45A-overexpression leads to the acquisition of markedmigratory activ-
ity (Figs. 7D and E). Accordingly, the morphological analysis of these
1524 I. Penna et al. / Biochimica et Biophysica Acta 1833 (2013) 1511–1526cells support their increased adhesiveness as HEK-45A cells, labeled
with α Anti-tubulin IgGs, exhibited, in immunoﬂuorescence analysis,
a strongly organized and extended net of tubulin ﬁbers that is not de-
tectable in HEK-M cells (Fig. 7F). Altogether, these experiments suggest
that besides a general increase of cell proliferation the overexpression of
45A might also favor transformation processes increasing malignant
potential.
To assess whether the increased expression of 45A RNA may favor
tumor formation in vivo, we injected subcutaneously 3 × 106 45A-
overexpressing HEK-293 and SKNBE2 cells and their Mock controls in a
pool of 20 NOD-SCID mice and evaluated possible differences in tumor
formation capacity and/or in tumor progression rate associated to 45A-
overexpression. In HEK-293 cells we did not observe a strike difference
in terms of capacity to form tumors since, after a prolonged time
(39 days after the injection), 5 out of 5 (100%) of the HEK-M-injected
mice and 5 out of 5 (100%) of the HEK-45A-injected mice developed
tumor nodules. This result suggests that the capacity of HEK-293 cells to
initiate tumors is partially independent on 45A-overexpression, as we
previously observed in vitro. Conversely, the tumor progression efﬁciency
was strongly different in HEK-45A- compared to HEK-M-injected mice.
All the mice in the control group showed a tumor nodule volume
≥5 mm3 after 39 days and 4 out of 5 mice already showed a volume
≥5 mm3 only after 30 days. On the contrary the group of HEK-45A-
injected mice reached a tumor nodule volume ≥5 mm3 after 23 days.
Moreover, 3 out of 5 of HEK-M-injected mice did not reach a tumor vol-
ume of 2000 mm3 at the time of sacriﬁce (58 days), whereas
HEK-45A-injected mice at the time of sacriﬁce had an averaged tumorFig. 8. 45A ncRNA expression favors cancer progression in vivo. Tumor development functio
nodules. In the inset of both ﬁgures it is represented the linear regression of the averagedvolume of 3689 mm3 (see supplementary online material S2A). These
results demonstrate that although our experimental setting using
HEK-293 cells does not allow to appreciate differences between the two
cell lines in terms of capacity to initiate tumors, it clearly demonstrates
that tumor progression potential might be signiﬁcantly affected by 45A
overexpression (Figs. 8A and S2A).
Next, we derived the polynomial interpolation by the average of
daily measurements of tumor volumes in order to obtain a repre-
sentative function of the tumor progression. As expected, the
growth trend of HEK-45A tumor masses is higher than HEK-M con-
trol masses. Indeed, calculating the averaged progression rate of
the growing nodules starting from their mass ≥5 mm3 to the time
of sacriﬁce we found that the averaged progression rate among
the HEK-M-injected mice was 98,529 mm3/day whereas that of
the HEK-45A-injected counterparts was 134,43 mm3/day (inset in
Fig. 8A). Altogether these results demonstrate that in HEK-293
cells the overexpression of 45A does not affect strongly the capacity
to initiate tumor but augments signiﬁcantly the tumor progression
rate and the growth speed of nodules.
Even clearer was the effect of 45A RNA overexpression on SKNBE2
cells. Here, we observed a signiﬁcant difference in tumor initiation
capacity between Mock- and 45A-injected mice as 29 days after the in-
jection 5/5 (100%) of the SKNBE2-45A-injectedmice and only 2/5 (40%)
of the SKNBE2-M-injected mice developed a tumor nodule ≥5 mm3
(See Supplementary Material online S2B for details). This is consistent
with a marked increase of SKNBE2 tumor formation capacity driven
by 45A RNA expression, according to the data obtained in vitro. Alson by the polynomial interpolation of A) HEK-293 tumor nodules and B) SKNBE2 tumor
progression rate.
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SKNBE2-45A-injected and SKNBE2-M-injected mice as in the control
group mice showed a 5 mm3 tumor nodule after an averaged 25th
day whereas after the same lag of time the averaged tumor mass of
the SKNBE2-45A-injected mice was 16.32 mm3. Again, SKNBE2-45A-
overexpressing tumor nodules grow faster than their Mock counter-
parts as resulting by the polynomial interpolation of daily averaged
measurements (Fig. 8B). Accordingly, the average progression rate
among SKNBE2-M-injected mice was 150.84 mm3/day whereas that
of their SKNBE2-45A-injected counterparts was 211.88 mm3/day
(inset in Fig. 8B). These results demonstrate that the overexpression
of 45A RNA affects signiﬁcantly both the capacity to initiate tumors
and the tumor progression/growth rate of nodules, providing a novel
link between APBB2 maturation, Aβ release and the regulation of cell
cycle.
4. Discussion
In the recent past an active role of FE65 protein family (and in partic-
ular that of APBB2) in neurodegeneration has been repeatedly proposed,
and its involvement in pathways that cross Alzheimer's disease has been
experimentally documented [11]. In particular, a role for APBB2 in mak-
ing APP available to γ-secretase cleavage, favoring its processing and
the release of Aβ in the extracellular space has been described [2]. In
light of this notion, if alternative APBB2 protein variants, with reduced
capability to interact with APP, are preferentially expressed, it is reason-
able to expect reduced formation of APBB2:APP protein complex, less
efﬁcient γ-secretase cleavage of APP, and, ultimately, decreased Aβ
secretion.
In this work we propose that the occurrence of this phenomenon
is driven and regulated by the synthesis of a newly identiﬁed pol
III-transcribed non-coding RNA. This transcript perturbs the matura-
tion of APBB2 pre-mRNA altering the ratio among alternative protein
variants. Although the speciﬁc biochemical features of each single
protein variant (and their afﬁnity for APP) still need to be established
in detail, in this work we show that by affecting APBB2 splicing, the
synthesis of 45A ncRNA ultimately conveys a reduced release of Aβ.
This phenomenon leads to a general increase of Aβ-x42/Aβ-x40
ratio, a condition that might favor amyloid aggregation also in the
absence of a generally increased release of total amyloid. In this
scenario, 45A RNA might, indirectly, contribute to the aggregation of
plaques and protoﬁbers [31] delineating its possible involvement in
neurodegeneration or in other conditions that imply impaired APP
processing or increased Aβ aggregation.
However, although the ﬁnding of a possible upstream regulator of
Aβ-dependent pathways is novel per se, in our view the most intrigu-
ing aspect of our ﬁndings is related to independent processes trig-
gered by 45A culminating with an unprecedented role of this small
RNA in the regulation of cell cycle and malignant potential. With
this respect, it is interesting to note that the strongly increased prolif-
eration rate demonstrated in 45A-overexpressing cells of different or-
igins is associated to the inhibition of the expression of cell cycle
control pathways and possibly to a decreased efﬁciency of DNA dam-
age response mechanisms. Indeed, a deﬁcient control of cell cycle
events and a weakened mitotic surveillance might be functional to
the strongly increased cell proliferation rate and with the marked
proneness to form tumors observed in 45A-overexpressing cells.
This aspect is of particular relevance also in the context of a possible
involvement of 45A RNA in AD since the effects of its overexpression
might ﬁt with the hypothesis of a cell cycle re-entry of post-mitotic
neurons as a fundamental event for AD-related neurodegeneration
[23,31–36]. Indeed, the abundant synthesis of this ncRNA in AD brain
would lead to consequences on chromosomal number and to the impair-
ment of DNA repair machinery previously proposed as a key event of AD
onset [37]. It is relevant from this point of view the role of Fe65 in chro-
mosomal stability and the intriguing possibility that the occurrence ofenhanced levels of 45A might disturb a homeostatic control of repairing
mechanisms at chromosomal level directly or in competition with Fe65.
Although we did not observe an increased formation of micronuclei
in HEK-293 cells overexpressing the 45A ncRNA following different
genotoxic stress, the results on cell survival suggest an impairment of
the DNA damage response in these cells. It has to be noted that the
overexpression of 45A signiﬁcantly increases the colony forming poten-
tial in SKNBE2 neuroblastoma but not in HEK-293 cells, indicating that
the it could favor malignant potential in a cell type-speciﬁc manner.
Thus, the impairment of DNA surveillance mechanisms in other neuro-
blastoma cells overexpressing the 45A ncRNA, (i.e. SKNBE2), deserves
further investigations.
The highly efﬁcient tumor formation capacity of 45A-overexpressing
cells concomitant to a perturbation of Aβ processing toward more
ﬁbrilogenic species might represent the ﬁrst molecular link between the
effects exerted by the same effector on Aβ release and on the regulation
of cell cycle. In this context 45A ncRNA biological effects bring to light
the possible co-regulation of the two phenomena and supports previous
observations on neurodegeneration, reconciling alternative hypothesis
for neurodegenerative processes. Indeed, our data are consistent with
the most recent literature showing that aneuploid neurons characterize
the brain of AD patients and that 3–4% of pyramidal neurons from AD
hippocampus are aneuploid [38] and might provide novel hints to join
together different hypothesis [39].
In conclusion, here we demonstrate that the perturbation of the
relative levels of different splice variants of APBB2 is crucial for the
determination of the cell phenotype although how and which is the
speciﬁc contribution of each variant to the phenotype observed is
unclear and deserves further studies. In this scenario, the determina-
tion of the level of synthesis of 45A RNA in neurodegeneration and/or
tumor samples deserves further investigations in order to bring to
light its contribution to cancer and/or neurodegeneration and a possi-
ble molecular link between these two pathologies.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.02.020.
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